Novel Cannabinoid Pharmaceuticals Provide Targeted Delivery of Cannabinoids and Reduced Delivery of Psychoactive THC to the Brain
LOS ANGELES, CA–Vitality Biopharma, Inc. (OTCQB: STVFD) (“Vitality” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced updates to its clinical development plans including the advancement of cannabosides for the treatment of inflammatory bowel disease.
Vitality Biopharma has developed a new class of cannabinoid prodrugs, known as cannabosides, which upon ingestion can enable the selective delivery of THC and cannabidiol (CBD) to the gastrointestinal tract. Site-specific delivery could enable oral drug formulations of cannabinoids to provide therapeutic benefits while reducing or avoiding the systemic delivery of THC into the bloodstream. Currently, high concentrations of psychoactive THC in the brain limit the dose of cannabinoids that can be used elsewhere in the body for treatment of pain and inflammation.
Independent clinical trial results suggest that cannabinoids will help induce remission in Crohn’s disease patients, and that the vast majority of inflammatory bowel disease patients experience symptomatic relief, including more than 75% of patients who report improvement in visceral pain and abdominal cramping. Approximately 1.4 million Americans are affected by inflammatory bowel diseases, including Crohn’s disease and ulcerative colitis. Most patients are diagnosed before age 30 and require life-long treatment.
“A long-standing pursuit of pharmaceutical and medical researchers is to provide the benefits of cannabinoids in a more targeted manner, and our cannabosides are poised to deliver this,” said Robert Brooke, CEO and Co-Founder of Vitality Biopharma. “Our drug development plans continue to highlight therapeutic areas that stand to benefit most, and gastroenterology is a clear example.”
More details of Vitality Biopharma’s clinical development plans for cannabosides may be found in its corporate presentation, which is available online: https://vitality.bio/investors/presentation/
About Vitality Biopharma (OTCQB: STVFD)
Vitality Biopharma is dedicated to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders. For more information, visit: www.vitality.bio. Follow us on Facebook, Twitter and LinkedIn.
Notice Regarding Forward-Looking Statements
This news release contains “forward-looking statements” as that term is defined in Section 27(a) of the United States Securities Act of 1933, as amended and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.